QQQ   437.93 (+0.61%)
AAPL   180.03 (-0.77%)
MSFT   409.55 (+0.45%)
META   489.05 (+1.04%)
GOOGL   137.24 (+0.63%)
AMZN   174.95 (+1.03%)
TSLA   199.87 (-1.07%)
NVDA   792.80 (+2.08%)
NIO   5.67 (+4.42%)
AMD   190.45 (+7.88%)
BABA   74.06 (-0.71%)
T   16.99 (+0.18%)
F   12.40 (+0.81%)
MU   89.85 (+0.16%)
CGC   3.27 (-2.68%)
GE   156.02 (+0.26%)
DIS   111.23 (+0.39%)
AMC   4.29 (-14.03%)
PFE   26.77 (-1.00%)
PYPL   60.23 (-0.03%)
XOM   104.55 (+0.22%)
QQQ   437.93 (+0.61%)
AAPL   180.03 (-0.77%)
MSFT   409.55 (+0.45%)
META   489.05 (+1.04%)
GOOGL   137.24 (+0.63%)
AMZN   174.95 (+1.03%)
TSLA   199.87 (-1.07%)
NVDA   792.80 (+2.08%)
NIO   5.67 (+4.42%)
AMD   190.45 (+7.88%)
BABA   74.06 (-0.71%)
T   16.99 (+0.18%)
F   12.40 (+0.81%)
MU   89.85 (+0.16%)
CGC   3.27 (-2.68%)
GE   156.02 (+0.26%)
DIS   111.23 (+0.39%)
AMC   4.29 (-14.03%)
PFE   26.77 (-1.00%)
PYPL   60.23 (-0.03%)
XOM   104.55 (+0.22%)
QQQ   437.93 (+0.61%)
AAPL   180.03 (-0.77%)
MSFT   409.55 (+0.45%)
META   489.05 (+1.04%)
GOOGL   137.24 (+0.63%)
AMZN   174.95 (+1.03%)
TSLA   199.87 (-1.07%)
NVDA   792.80 (+2.08%)
NIO   5.67 (+4.42%)
AMD   190.45 (+7.88%)
BABA   74.06 (-0.71%)
T   16.99 (+0.18%)
F   12.40 (+0.81%)
MU   89.85 (+0.16%)
CGC   3.27 (-2.68%)
GE   156.02 (+0.26%)
DIS   111.23 (+0.39%)
AMC   4.29 (-14.03%)
PFE   26.77 (-1.00%)
PYPL   60.23 (-0.03%)
XOM   104.55 (+0.22%)
QQQ   437.93 (+0.61%)
AAPL   180.03 (-0.77%)
MSFT   409.55 (+0.45%)
META   489.05 (+1.04%)
GOOGL   137.24 (+0.63%)
AMZN   174.95 (+1.03%)
TSLA   199.87 (-1.07%)
NVDA   792.80 (+2.08%)
NIO   5.67 (+4.42%)
AMD   190.45 (+7.88%)
BABA   74.06 (-0.71%)
T   16.99 (+0.18%)
F   12.40 (+0.81%)
MU   89.85 (+0.16%)
CGC   3.27 (-2.68%)
GE   156.02 (+0.26%)
DIS   111.23 (+0.39%)
AMC   4.29 (-14.03%)
PFE   26.77 (-1.00%)
PYPL   60.23 (-0.03%)
XOM   104.55 (+0.22%)

Rocket Pharmaceuticals (RCKT) Competitors

$29.43
+0.40 (+1.38%)
(As of 02:34 PM ET)

RCKT vs. GLPG, EVO, MOR, AMPH, HCM, CRNX, ARVN, VERA, CORT, and IDYA

Should you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include Galapagos (GLPG), Evotec (EVO), MorphoSys (MOR), Amphastar Pharmaceuticals (AMPH), HUTCHMED (HCM), Crinetics Pharmaceuticals (CRNX), Arvinas (ARVN), Vera Therapeutics (VERA), Corcept Therapeutics (CORT), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical preparations" industry.

Rocket Pharmaceuticals vs.

Galapagos (NASDAQ:GLPG) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment, earnings and community ranking.

Galapagos has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500.

Galapagos currently has a consensus target price of $42.00, suggesting a potential upside of 18.64%. Rocket Pharmaceuticals has a consensus target price of $54.00, suggesting a potential upside of 82.56%. Given Galapagos' stronger consensus rating and higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Galapagos.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galapagos
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.20
Rocket Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
3.00

Rocket Pharmaceuticals has lower revenue, but higher earnings than Galapagos. Galapagos is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galapagos$532.48M4.38-$229.68M-$2.29-15.46
Rocket PharmaceuticalsN/AN/A-$221.86M-$2.94-10.10

In the previous week, Rocket Pharmaceuticals had 18 more articles in the media than Galapagos. MarketBeat recorded 28 mentions for Rocket Pharmaceuticals and 10 mentions for Galapagos. Galapagos' average media sentiment score of 0.43 beat Rocket Pharmaceuticals' score of 0.42 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Galapagos
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
Rocket Pharmaceuticals
8 Very Positive mention(s)
5 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Galapagos received 97 more outperform votes than Rocket Pharmaceuticals when rated by MarketBeat users. However, 72.16% of users gave Rocket Pharmaceuticals an outperform vote while only 64.85% of users gave Galapagos an outperform vote.

CompanyUnderperformOutperform
GalapagosOutperform Votes
465
64.85%
Underperform Votes
252
35.15%
Rocket PharmaceuticalsOutperform Votes
368
72.16%
Underperform Votes
142
27.84%

Rocket Pharmaceuticals has a net margin of 0.00% compared to Rocket Pharmaceuticals' net margin of -26.25%. Rocket Pharmaceuticals' return on equity of -2.60% beat Galapagos' return on equity.

Company Net Margins Return on Equity Return on Assets
Galapagos-26.25% -2.60% -1.46%
Rocket Pharmaceuticals N/A -52.52%-46.77%

29.7% of Galapagos shares are owned by institutional investors. Comparatively, 94.5% of Rocket Pharmaceuticals shares are owned by institutional investors. 2.9% of Galapagos shares are owned by company insiders. Comparatively, 31.1% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Rocket Pharmaceuticals beats Galapagos on 12 of the 17 factors compared between the two stocks.


Get Rocket Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RCKT vs. The Competition

MetricRocket PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.68B$6.59B$4.94B$7.48B
Dividend YieldN/A2.81%2.87%3.87%
P/E Ratio-10.108.61217.8615.69
Price / SalesN/A1,085.773,209.89201.58
Price / CashN/A19.3194.4854.64
Price / Book4.594.754.464.68
Net Income-$221.86M$153.09M$112.73M$210.91M
7 Day Performance2.38%6.38%4.91%2.78%
1 Month Performance1.92%11.29%10.02%3.89%
1 Year Performance54.55%5.75%12.58%8.07%

Rocket Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GLPG
Galapagos
0.5717 of 5 stars
$39.42
-0.6%
$42.33
+7.4%
-4.4%$2.60B$532.48M-17.211,338Upcoming Earnings
EVO
Evotec
2.441 of 5 stars
$7.38
+0.3%
$14.00
+89.7%
N/A$2.62B$791.73M0.004,952
MOR
MorphoSys
0.6386 of 5 stars
$17.59
+0.6%
$11.53
-34.5%
+290.7%$2.65B$293.27M45.10544Short Interest ↑
AMPH
Amphastar Pharmaceuticals
4.9421 of 5 stars
$52.45
-3.0%
$68.00
+29.6%
+68.6%$2.51B$498.99M20.491,615Short Interest ↑
News Coverage
Gap Down
HCM
HUTCHMED
1.7551 of 5 stars
$14.41
-1.2%
$29.70
+106.1%
-3.2%$2.51B$426.41M0.002,025Gap Up
CRNX
Crinetics Pharmaceuticals
3.5606 of 5 stars
$37.42
-1.1%
$44.90
+20.0%
+122.5%$2.50B$4.74M-10.28210Earnings Report
Analyst Report
Short Interest ↓
News Coverage
Positive News
ARVN
Arvinas
3.092 of 5 stars
$50.60
-3.3%
$54.40
+7.5%
+50.3%$2.78B$131.40M-9.15415Earnings Report
Analyst Report
Insider Selling
Short Interest ↑
Analyst Revision
News Coverage
Gap Up
VERA
Vera Therapeutics
1.427 of 5 stars
$44.69
-2.8%
$26.29
-41.2%
+516.6%$2.35BN/A-15.4149Gap Up
CORT
Corcept Therapeutics
4.6753 of 5 stars
$22.58
-0.6%
$33.79
+49.6%
+13.2%$2.34B$482.38M23.77299
IDYA
IDEAYA Biosciences
3.2691 of 5 stars
$44.01
-6.6%
$36.73
-16.5%
+156.9%$2.84B$50.93M-22.57122Upcoming Earnings
Analyst Revision

Related Companies and Tools

This page (NASDAQ:RCKT) was last updated on 2/29/2024 by MarketBeat.com Staff